MITF and melanoma: In conclusion, MITF loss drives melanoma cell plasticity and phenotypic switching that correlates with reduced differentiation and immunogenicity, this loss also limits antitumor efficacy through the production of an inflammatory milieu that shapes an immunosuppressive TME.